Abstract Research studies focusing on parents' perspectives of pharmacological clinical trials have not kept pace with the number of emerging pharmacologic clinical trials in Down syndrome (DS) and Fragile X syndrome (FXS). Since individuals with DS or FXS have limited cognitive ability to make decisions about their participation in clinical trials, it is important to consider the parents' perspectives and explore the ways in which decisions are made for their children. Using a semi-structured interview, we enrolled 9 parents of a child(ren) with FXS and 15 with a child with DS to analyze their views, experiences, and knowledge of pharmacological clinical trials. Although our study is preliminary in nature, it revealed that parents are generally supportive of pharmacological clinical trials, yet there may be concerns about safety and long-term implications and consideration for their child in the decision process. There is also parental misunderstanding of the objectives of pharmacological clinical trials; thus, it is important for pharmaceutical companies, study investigators, clinicians/medical professionals, and parent advocacy groups to collaborate to provide appropriate and up-to-date educational resources that fully explain the risks and benefits of clinical trials.
Introduction
Fragile X syndrome (FXS), resulting from a mutation in the FMR1 gene, is the most common inherited condition causing intellectual disability and autism (Hagerman et al. 2012) . As well, Down syndrome (DS) is a chromosomal condition, resulting from the presence of a third chromosome 21, and leads to the most common form of intellectual disability (Reeves and Garner 2007) . Recent research has helped to uncover the neurological pathways that are disrupted in both conditions as a consequence of the genetic etiology. For this reason, advances in pharmacological clinical trials targeting these pathways in FXS and DS have progressed rapidly.
Current treatments in FXS and DS are symptom-based, focusing on interventional therapies, educational resources, and medications that may help with comorbid behavioral symptoms, such as attention-deficit/hyperactivity disorder (ADHD), anxiety, or aggression (Hagerman et al. 2012; Reeves and Garner 2007) . As an example, in FXS, behavioral and psychological issues are prominent with implications for daily living and social function. The behavioral features include social avoidance, anxiety, obsessive-compulsive disorder, hyperarousal to sensory stimuli, autistic behavior (e.g., hand flapping, poor eye contact, perseverative behavior or speech), hyperactivity, impulsivity, inattention, self-injurious behavior, and aggression (Berry-Kravis and Potanos 2004) . The most promising therapeutic compound is the mGluR5 antagonist, which entered Phase 2 clinical trials in two large studies including the AFQ056/mavoglurant (Novartis) for 12-45 years old and 5-50 years old with RO4917523/ basimglurant (F. Hoffmann-La Roche). Additionally, Seaside Therapeutics conducted a large Phase 3 clinical trial in individuals with FXS age 5-50 year old investigating arbaclofen (STX209), a GABAb agonist shown to reduce the amount of glutamate released into the synapse. These studies did not move forward since the results did not meet the primary endpoints to demonstrate if the study drug is effective in treating the core behavioral deficits in FXS (Berry-Kravis et al. 2016a, b) . Other completed FXS clinical trials include the Phase 2 trial with Metadoxine extended-release for ADHD (Alcobra) and Phase 2 trial in insulin growth factor hormone (NNZ-2566; Neuren) .
Individuals with DS have a wide array of medical complications including congenital heart defect, obstructive sleep apnea, hearing loss, hypothyroidism, and gastrointestinal issues (Bull and Committee on Genetics 2011) . With advances in medical and surgical treatments, the life expectancy of individuals with DS has increased. However, treatment targeting the core deficits in cognition does not currently exist and continues to be a major barrier for many individuals with DS. Previous pharmacological clinical trials have focused on increasing cholinergic function with emphasis on those with and without a comorbid condition of dementia or early-onset Alzheimer's. As an example, donepezil has shown limited or no benefits in clinical trials for individuals with DS Kishnani et al. 2004; Kishnani et al. 2009; Prasher et al. 2002) . Memantine, a N-methyl-D-aspartate-receptor antagonist, was studied in a clinical trial in 40 young adults with DS with negative results on the primary endpoints (Boada e t a l . 2 0 1 2 ) . B a s m i s a n i l ( H o f f m a n n -L a R o c h e Pharmaceuticals) is a selective GABAA α5 negative allosteric modulator (NAM) that has been investigated in two multicenter, Phase 2, randomized, double-blind, placebocontrolled studies to improve cognition in DS in a 26 week treatment study of adolescents and adults ages 12 to 30 years (ClinicalTrials.gov identifier NCT02024789) and a pediatric population between 6 to 11 years of age (ClinicalTrials.gov identifier NCT02484703). Unpublished results from the Phase 2 study in young adults and adolescents with DS (12 to 30 years old) did not meet the primary outcome which lead to early discontinuation of the study in the pediatric population (age 6-11 years).
Research studies focusing on parents' perspectives on pharmacological clinical trials have not kept pace with the number of emerging pharmacologic clinical trials in DS and FXS (Schaefer et al. 2015; Gross et al. 2015; Berry-Kravis et al. 2016a, b) . Additionally, limited number of studies have described caregivers' perspectives and attitudes towards clinical trials in DS and FXS (Heller et al. 2006; Bailey et al. 2014; Cross et al. 2016) . Since individuals with DS and FXS have limited cognitive ability to make decisions about their participation in clinical trials, consideration of parental perspectives is an ethical imperative, as is exploration of the ways in which decisions are made for their children. Our study objective is to conduct a semi-structured interview with parents with a child(ren) with either DS or FXS to understand their views, experiences, and knowledge of pharmacological clinical trials.
Methods Participants
Parents of individuals with DS and parents of individuals with FXS were eligible to participate in the study. In order to include a diverse group of participants, there were no limitations on the age of the child or whether they had previously participated in clinical trial(s). The participants with DS were recruited through the Down Syndrome Center at Emory University. The participants with FXS were recruited through parent support groups sponsored by FRAXA and the National Fragile X Foundation. A study invitation was posted on a FRAXA listserv, and the Georgia chapter of the National Fragile X Foundation sent an email invitation to its members. Additionally, an invitation was also sent to parents of individuals who had participated in DS or FXS clinical trials at Emory University.
Procedures
Interested participants were first contacted via email to further describe the study. Once the participant consented to the study, a phone interview was scheduled. There was no compensation for participation. This study was approved by the Institutional Review Board at Emory University. All phone interviews were conducted by the same trained interviewer, who had no direct involvement with the FXS or DS Centers at Emory University. Each interview was audio-recorded after verbal informed consent and HIPAA authorization were obtained. A verbal consent is done via a waiver of documentation of consent conducted during the phone interview. A short demographic survey recording race/ethnicity, education level, household income, and source of health insurance preceded the interview. After demographic information was collected, the interviewer assessed the participant's knowledge about pharmacological clinical trials. If the participant was not familiar with the definition or process of a pharmacological clinical trial, a brief explanation of the purpose of clinical trials was provided (script available from authors). A study-specific interview guide was used to conduct the semi-structured interviews. Questions focused on thefollowing areas: (1) health and behavioral functioning of the child, (2) attitudes towards pharmacological clinical trials, and (3) decision-making process for participation in clinical trials and use of medications. Overall, each interview was approximately 30 min in duration.
Data Analysis
Demographic data were analyzed using descriptive statistics. The recorded interviews were transcribed using Dragon Dictation Software (Nuance Communications, Burlington, MA). Any names mentioned during the interview and all identifiers were removed from transcriptions prior to analysis. Representative comments made by participants that are included in Results are parenthetically referenced with the participant's study number and the child's condition, 'F' indicates FXS, 'D' indicates DS. We used an inductive approach to analyze data, which was not guided by any hypotheses or theoretical framework. A subset of interview transcripts was first open-coded for broad themes by four team members. Once the four team members reached consensus on the study codes, two members of the research team used this code book and independently coded each interview transcript. Any disagreements in coding were discussed by the two team members until a consensus was reached.
Results

Demographic Information
The study included 24 caregivers (22 mothers and 2 fathers); however, two caregivers have two children with FXS. For this reason, there are a total of 26 individuals with either DS or FXS. Among the nine parents with a child(ren) with FXS, 5 families had enrolled their child(ren) in pharmacological clinical trials. None of the 15 parents in the DS group had children who participated in pharmacological clinical trials. Children's ages and demographics of parents are indicated in Fig. 1 and Table 1 , respectively. Eleven of the 15 children with DS are males, and nine of the 11 children with FXS are males.
Child's Health and Behavioral Functioning
Nineteen of the 26 children currently have no medical problems, as reported by their parents. Five parents of individuals with DS described previous medical problems including cardiac issues, hypothyroidism, diabetes, celiac disease, and reflux. Furthermore, 21 of the 24 participants responded affirmatively that their child's overall health was good despite their child experiencing medical problems. One parent who responded in this way described her son's medical problems by saying, BFirst came Down syndrome, and then came the thyroid problem, and then came the Hashimoto's, and then came the celiac, and then came the diabetes, so they just surround him.^(D8). However, to the next question, BOverall would you say that he's doing well and in good health?^she responded, B[y]es. Yes, he is.^(D8). Three parents were hesitant to say, Byes,^or questioned the term, Bgood health.^One parent explained: In addition, four out of nine parents of individuals with FXS and six out of 15 parents of individuals with DS reported that their child(ren) have behavioral problems. The behavioral concerns differ between the two groups; anxiety and hyperactivity were most frequently reported in FXS and stubbornness and immaturity in DS.
Parental Perception toward Pharmacological Clinical Trials
After the introduction of the concept of Bclinical trials,^we asked parents about their general attitudes towards pharmacological clinical trials. Of note, two coders independently coded the question about each parent's feelings regarding clinical trials. Both reviewers then discussed each participant and the code to make sure they were consistent. Among parents of children with FXS, all nine had a positive attitude. Among those with DS, the responses were varied: nine were positive, three were negative, and three were neutral.
Among the positive responses, one parent explained, BI think [clinical trials] are a miracle, it's an amazing time to live in and we're honored to be a part of something, to be actually looking at fragile X itself and not just the symptoms.^(F15). One other parent responded, BIf we can do something that helps us and helps research out too, to help better somebody else's life and better his life too-I think it's a good thing because it could help everybody.^(F11). A parent of a child with DS explained, BI have positive feelings about them just as I think we can learn from them.^(D2). Interestingly, two parents who had positive responses about clinical trials stated that they would be reluctant to involve their child in a trial. One explained, B[drug trials] are necessary, I wouldn't volunteer my children for them.^(D20). She further explained, BI would really have to know that there would be minimal [harm] to my son. I would be devastated if I did something that you know cause [d] more harm to him.^(D20). The other parent explained, BI'm not sure because of all of his health problems. I'm so afraid to introduce anything right now.^(D8). Of the three parents in the DS group who were negative about trials, their comments included: BI'm kind of iffy about [trials], because my concern would be the long-term effect of the drug and my concern would also be if … there's any … side effects.^(D3). Additionally, Bas a parent I would not expose my child to a clinical drug trial.^(D22). One neutral parent stated, BI guess it would be a drug by drug basis. I mean some of them you're not going to know any side effects at all.^(D9).
Decision-Making Process in a Pharmacological Clinical Trial
Common themes emerged in the interview when parents discussed their attitudes towards pharmacological clinical trials and medications (Fig. 2) .
Motivation to be in a Clinical Trial
Parents described their motivation to have their child in a pharmacological clinical trial either as hoping for improvements in their child's health (n = 13) or as wanting to help other individuals with the same genetic condition (n = 5), or both (n = 4). For those who expected improvement in their child's behavior, cognition, or communication, the priorities differed by genetic condition. Among parents of children with FXS (n = 9), three indicated that they would like improvement. Parents also mentioned wanting to see communication (n = 2) and cognitive (n = 1) improvements. Among those with DS (n = 15), five parents would like their child's cognition to improve. One parent also mentioned wanting to see behavioral improvements.
In assessing the correlations between a child's overall behavioral/health status and the parent's interest in pharmacological clinical trial participation, 12 of the 21 parents who described their children as Bdoing well^wanted their child to be enrolled in a pharmacological clinical trial or had already involved them in a trial. Of the three parents who were hesitant to describe their child as doing well, two wanted their child in a trial and one was unsure of whether she would enroll her child.
One participant mentioned her hope that her child be given the active medication, as opposed to a placebo. She explained, BI think we both felt like it was pretty cool to be contributing to science but we were both disappointed he got the placebo which we found out at the end after we were done.^(F14)
Concerns about Impact of Pharmacological Treatments
Eighteen parents discussed concerns about enrolling their child in a pharmacological clinical trial or having their child take investigational medications. Fifteen out of the 18 parents expressed concerns about the safety of the investigational study medicine, such as long-term and transient side effects. Five out of the 24 parents described logistical concerns, such as proximity to a clinical trial site and how the trial schedule would affect everyday life. Throughout the interviews, four out of 24 participants stated they had cautious or negative feelings towards medication in general. For example, one parent explained, Bif we can manage behaviors with other things besides medicine, that's the way I tend to go.^(D20). Two parents explained that there were personality traits about their child(ren) that they would not want to be affected by any medication. For example, Bwe [have] a child with Down syndrome and they're so happy and carefree and we wouldn't want that to change.^(D19). Another parent compared pharmacological intervention targeting the core deficits to changing a trait or characteristic: Blike if I have a headache I take an aspirin right? but if I am five-foot-four-inchesand there was a medicine that I could take to make me taller you know I'm not going to take that.( D23). In response to being asked her feelings towards pharmacological clinical trials, one other participant said, BI guess it would depend … what [the study medicine is] purporting to do, and not against individuals being who they are cognitively… if it's something that has more of a global benefit than just targeting some kind of intelligence increase, then I might be for it, but generally I just believe, let people be who God created them to be.^(D5).
In contrast, one parent explained that she would give her daughter anything: Bthe retardation, IQ factor, gosh if there was something out there that would guarantee her IQ to raise her understanding, absolutely I'd look into it. We do know that she will succeed, but if I can give her more, heck yeah, I would.
I'd do [it] with my normal kids too.^(D9).
Participants were asked BIf a medicine (targeting core deficits) came on the market would you consider getting a prescription for your child?^All 24 of the parents said Byes,ĥ owever ten of those said that their Byes^would be contingent upon certain caveats, such as health insurance coverage, needing more information, and knowing which symptoms the drug would target. Parents were also asked whether they would put their child(ren) on a medicine for an entire lifetime. Thirteen said, Byes,^and two said, Bno.^The remaining nine were undecided or had caveats and said decisions would depend on long-term side effects, the child's input on the decision to take the drug, and the child's age at the time the decision would be made.
Child Involvement in Decision-Making for Participation in Clinical Trials
The ability to involve their children in making the decision for participation in a trial was also identified as an important aspect of the decision-making process. Of the five parents who had enrolled their child(ren) in a FXS pharmacological clinical trial, two parents involved their child in that decision. Among parents who had not been involved in trials, seven were adamant that they would involve their child in the decision-making. For example, B[w]e discuss so many things with him that we would, you know, discuss all of this with him. He's really fortunate to be able to comprehend a great deal.^(D21). However, four parents said they would definitely not involve their child in the decision-making process. For example, BI'm sorry, he doesn't have the mental capacity to decide.^(D16). The remaining eight parents explained that multiple factors would determine potential child involvement, including the child's cognitive function, understanding, and age. One parent explained, BI would probably need to make [the decision for him to take a lifelong drug] when he is old enough to make the decision too, I guess.^(D4). Then, in response to being asked Bin terms of the clinical trial, would you want to include his input and wait until he is older or would you not necessarily?^she responded, Bum, not necessarily but I mean if it's an optional drug and it's something that he would take after he was old enough to decide whether or not he wanted to take it then… he would control that.^(D4). Another parent expressed concern for the child's vulnerability by saying, BI think because of the cognitive delay, kids with DS are going to be very easily swayed by people who may or may not have their best interest at heart … so I'd be very careful about how I involved him. I would want his opinion, but I would also want him to really understand the decision.^(D23).
Background Knowledge and Opportunity to Discuss with Others
Background knowledge about pharmacological clinical trials varied among the parents in this study. Some parents had independently researched ongoing pharmacological clinical trials by speaking with physicians, other parents involved in clinical trials, or researchers. Six out of the 19 parents who did not have a child previously or currently participating in a pharmacological clinical trial stated that they needed more information, BI just don't know enough about [clinical trials]…so I would really have to be educated that this was really the right thing.^(D23). Comments throughout interviews on knowledge of pharmacological clinical trials also indicated that participants misunderstood the purpose of these trials. One participant would only enroll her child in a trial if the study medication being tested already had Food and Drug Administration (FDA) approval, and another would only want her children to participate in a trial if there were no side effects or possible long-term harm. In terms of parents' decision to enroll their child(ren) in a pharmacological clinical trial, 23 out of the 24 participants spoke or would speak with other people to help make the decision. The most frequently mentioned consultants included immediate family members (spouse or children), medical professionals (researchers, physicians, and genetic counselors), FXS/DS parent community, and extended family members (e.g., grandparents and uncles).
Discussion
This study explores and gauges parental perspective on pharmacological clinical trials, using DS and FXS as examples since these are common genetic conditions with longstanding histories of pharmacological clinical trials. At the time of our study, there were multiple safety and efficacy Phase 2 and 3 FXS clinical trials and one DS clinical trial in Phase 1 evaluating safety. The FXS clinical trials also included a wider range of ages (5-45 years for FXS vs. 18-30 years for DS). For these reasons, parents of children with FXS may have had more access to information regarding clinical trials through their physicians and/or parent advocacy groups.
Some aspects of the decision-making process include motivation to be in the trial, concerns about pharmacological treatment, child involvement in the decision-making about participation in the trials, knowledge of clinical trials, and opportunity to seek further information about clinical trials. Parents were generally supportive of clinical trials and recognized that pharmacological clinical trials are necessary to advance research, although there may be little or no direct benefit to them. Among parents of children with FXS, all nine had a positive attitude about pharmacological clinical trials while nine of 15 parents of children with DS had a positive response. Combined with other responses in the interviews, it appears that pharmacological clinical trials or pharmaceutical intervention are still met with some skepticism by parents when they involve their children. One of the concerns that parents of children with DS described includes the impact on their child's personality or positive attributes of being Bcarefree and happy^from these medications.
Furthermore, our results indicate that some parents may not fully grasp the purpose of clinical trials based on their perception of the study objectives. As an example, they would allow their child to participate in clinical trials for FDA-approved medications or those that guaranteed there would be no safety issues during the course of the study and/or long term side effects. As these clinical trials are in the early stages, efficacy and long-term safety data are not yet available.
The Bdouble-blind^aspect of trials was also mentioned as a parental concern as parents prefer to have their child take the active medication over a placebo. As such, the majority of parents also expect to notice improvements during the course of the study. Other studies have explored this common phenomenon, referred to as the Btherapeutic misconception^and explained it as Ba widely recognized problem in informed consent that occurs when subjects consent to participate in clinical research because of the belief that they will receive the same individually focused treatment that they would receive in a non-research clinical context.^ (Lidz and Appelbaum 2002) . If parents are expecting improvement when participating in pharmacological clinical trials, it can confound the study outcome resulting in a placebo response in which the Bplacebo^group shows change from baseline. For this reason, investigators need to set the right expectation for families when explaining the purpose of pharmacological clinical trials. This will also help parents to have a clear understanding of the study objectives so they will not be disappointed if their child shows no benefit from participating in clinical trials.
Parents recognized that it may not be feasible to have their child be part of the decision-making for participation in pharmacological clinical trials due to their child's intellectual disability; however, they stated they would involve their children in these discussions with advancing age and development. A recent study posed similar questions, with respect to how much parents would involve their children in a decision to participate in a FXS pharmacological clinical trial: 51% of parents of males with FXS and 22.4% of parents of females with FXS responded that their children were B[n]ot at all capable^of making a decision about study participation (Bailey et al. 2014 ). Approximately 7.9% of parents of males with FXS and 39.7% of parents with females with FXS responded that their child was B[f]ully capable^of making such a decision. This suggests that since there is variability in decisional abilities, researchers should develop strategies to maximize participation in the assent or consent process when appropriate.
Our study results reveal that parents recognize the importance of pharmacological clinical trials in advancing science; however, several factors are important in their consideration to participate in these trials. For these reasons, it is important that pharmaceutical companies, investigators, clinicians/medical professionals, and parent advocacy groups collaborate to provide educational material with up-to-date information about risks and benefits of pharmacological clinical trials information related to the basics of clinical trials. This may be helpful prior to initiating the study as parents will have time to review and ask questions. Prior to their enrolling participants in the study, investigators should set clear expectations for parents. For example, parents should be aware that there are different phases of clinical trials (e.g, early Phase 1 and 2 may evaluate safety as a primary objective vs. late Phase 3 may evaluate efficacy as a primary objective). Also, a double-blind design is necessary in order to preserve the integrity of the study and accurately assess the safety and efficacy of the investigational medication compared to placebo. Additionally, the IRB should pay close attention to the consenting process for individuals with intellectual disability, and warrant documentation of legal guardianship when appropriate.
Study Limitations
Although there are significant strengths in conducting indepth interviews to understand parental perceptions of pharmacological clinical trials, we note that our sample size is small and include both DS and FXS. The majority of our participants were recruited from Emory University, and some were participating in clinical trials at the time of this study. As such, our sample size is not homogenous and may not be representative of all parents. All five of the FXS caregivers who have a child who has participated in clinical trials reported improvement, which may also affect their overall perception of clinical trials. Notably, parents who had neutral or negative attitudes towards clinical trials had not enrolled their child in a drug trial at the time of this study. Our results are preliminary which we hope will spark interest in future studies particularly with increasing numbers of pharmacological clinical trials in DS and FXS and other neurodevelopmental disabilities.
Practice Implications and Recommendations
Moving forward, this study can help researchers understand the needs and expectations of parents whose children with intellectual disability are invited to be involved in clinical trials. In order to respond to parents' concerns of how pharmacological treatments might impact their child, future researchers could interview parents of children who do not have FXS or DS but do take medication for behavioral problems such as hyperactivity, social withdrawal, and anxiety in an effort to explore whether concerns noted in this study are limited to the population of individuals with FXS and DS. Lastly, similar qualitative studies should be performed after more pharmacological clinical trials are conducted in these disorders, so that parents with experience in deciding whether to enroll their children can discuss their actual decision-making process.
